Catalyst Pharmaceuticals, Inc. (CPRX)
| Market Cap | 1.66B |
| Revenue (ttm) | 191.76M |
| Net Income (ttm) | 66.92M |
| Shares Out | 104.07M |
| EPS (ttm) | 0.61 |
| PE Ratio | 26.20 |
| Forward PE | 19.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 841,279 |
| Open | 16.13 |
| Previous Close | 16.10 |
| Day's Range | 15.92 - 16.50 |
| 52-Week Range | 5.61 - 22.11 |
| Beta | 1.26 |
| Analysts | Buy |
| Price Target | 20.30 (+27.35%) |
| Earnings Date | Mar 15, 2023 |
About CPRX
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atroph... [Read more]
Financial Performance
In 2021, CPRX's revenue was $140.83 million, an increase of 18.27% compared to the previous year's $119.07 million. Earnings were $39.48 million, a decrease of -47.35%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is $20.3, which is an increase of 27.35% from the latest price.
News
Here is What to Know Beyond Why Catalyst Pharmaceuticals, Inc. (CPRX) is a Trending Stock
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence
World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio
Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
3 Reasons Growth Investors Will Love Catalyst (CPRX)
Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
Announced Earlier Today-Notice Received from ANDA Filer for FIRDAPSE®
Is Trending Stock Catalyst Pharmaceuticals, Inc. (CPRX) a Buy Now?
Zacks.com users have recently been watching Catalyst (CPRX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
CORAL GABLES, Fla., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (NASDAQ: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...
Biotech's Blockbuster Week: 3 Stocks to Watch
In a strong week for the market, biotech dominated. Today we will cover 3 promising stocks in the space.
2 Biotechs Making Waves With A Single Product in their Pipeline
Catalyst Pharmaceuticals and Harmony Bioscience each have a single product in their respective pipelines, and both show incredible promise.
Is Most-Watched Stock Catalyst Pharmaceuticals, Inc. (CPRX) Worth Betting on Now?
Catalyst (CPRX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Biotech: 3 Profitable Bios Worth Owning
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval.
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
Acquisition Expands The Company's Commercial Portfolio With An Established U.S. Marketed Product
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Catalyst Pharmaceutical (CPRX) Crossed Above the 20-Day Moving Average: What That Means for Investors
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Catalyst (CPRX) Up 8.9% Since Last Earnings Report: Can It Continue?
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now
Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?
Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates
Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates
Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceuticals Reports Record Third Quarter 2022 Financial Results and Provides a Corporate Update
Achieved Record Q3 2022 FIRDAPSE® Net Revenue of $57.2 Million, a 59.3% YoY Increase
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?
On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.
Catalyst Pharmaceuticals Named BioFlorida 2022 Company of the Year
CORAL GABLES, Fla., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and ...